Lexicon Pharmaceuticals reported its Q1 2025 earnings, revealing a smaller-than-expected loss per share and a significant drop in revenue compared to forecasts. The company posted an EPS of -$0.07 ...

LITTLE ROCK (KATV) — Students at Mills University Studies High School are set to benefit from a new partnership with Lexicon Inc. that promises to bring real-world career training directly into ...

THE death of Pope Francis on Easter Monday, April 21, started a series of Catholic ceremonies that were not always witnessed by the faithful and the world in general. Along with these ancient rites ...

Lexicon Pharmaceuticals has a 52 week low of $0.28 and a 52 week high of $2.45. The firm has a market cap of $140.48 million, a price-to-earnings ratio of -0.76 and a beta of 1.04.

Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for the preclinical obesity drug LX9851. The company abandoned its underperforming heart failure drug and ...

Lexicon Pharmaceuticals shares jumped nearly 75% in early trading Friday after the biopharmaceutical company inked a license agreement potentially worth $1 billion with Danish drug maker Novo ...

Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and near-term milestone payments THE WOODLANDS ...

THE WOODLANDS, Texas, March 28, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S ...

Lexicon Pharmaceuticals secured a licensing deal with Novo Nordisk for LX9851, with potential payments totaling $1 billion-plus royalties. Preclinical data show that LX9851 enhances weight loss ...

March 28 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is licensing Lexicon Pharmaceuticals' (LXRX.O), opens new tab experimental obesity drug in a deal worth up to $1 billion, the Danish ...

LITTLE ROCK, Ark., March 19, 2025 (GLOBE NEWSWIRE) -- Lexicon has announced plans to expand its corporate headquarters and steel fabrication operations in Little Rock, Arkansas, creating 60 new jobs.

Lexicon Pharmaceuticals is yet again defending a mixed set of data on its non-opioid pain prospect. The biotech focused on low-dose results from its latest phase 2 trial, rather than the overall ...